As of May 30, 2025
SPDR S&P Pharmaceuticals ETF (ARCA: XPH)
Ticker | Name | Share % | |
---|---|---|---|
AXSM | Axsome Therapeutics, Inc. | 3.81% | |
VTRS | Viatris Inc. | 3.82% | |
ITCI | Intra-Cellular Therapies Inc | 3.60% | |
BMY | Bristol-Myers Squibb Co. | 3.65% | |
PFE | Pfizer, Inc. | 3.67% | |
CORT | Corcept Therapeutics Inc | 5.67% | |
JNJ | Johnson & Johnson | 3.83% | |
OGN | Organon & Co | 3.55% | |
CTLT | Catalent, Inc. | 3.84% | |
ZTS | Zoetis, Inc. | 4.19% | |
RPRX | Royalty Pharma | 4.02% | |
LLY | Eli Lilly & Co. | 3.61% | |
JAZZ | Jazz Pharmaceuticals Plc | 4.19% | |
PRGO | Perrigo Co. Plc | 3.92% | |
TARS | Tarsus Pharmaceuticals Inc | 4.11% | |
ELAN | Elanco Animal Health Inc. | 5.20% | |
PBH | Prestige Consumer Healthcare Inc | 3.92% |
The XPH ETF is currently trading at $0.00, which represents a 0.00% change. Over the past 52 weeks, the ETF has traded as high as $48.76 and as low as $35.22.
The expense ratio of XPH is 0.35%. This represents the annual fee that all funds or ETFs charge their shareholders.
The total Assets Under Management (AUM) for XPH is 149.89M. This represents the total market value of the assets managed by the ETF.
XPH follows a Mid Cap Blend investment style.
The top holdings of XPH include: AXSM (3.81%), VTRS (3.82%), ITCI (3.6%), BMY (3.65%), PFE (3.67%). These represent the largest positions in the ETF's portfolio.
Average daily volume data for XPH is currently not available.